NewsfeedFollowed Companies

Ionis's Competitors, Revenue, Number of Employees, Funding and Acquisitions

Ionis is a drug discovery company that develops and commercializes ribonucleic acid-targeted therapeutics for cardiovasc... Read more

Based on data from Ionis's latest SEC filings

Annual Revenue

Based on data from Ionis's latest SEC filings

Employees

Brett P. Monia's photo - CEO of Ionis

CEO

Brett P. Monia

CEO Approval Rating

84/100

OVERVIEW

Founded:

1989

Headquarters:

CarlsbadCalifornia

Status:

PublicIndependent Company of NASDAQIONS

Industry Sector:

Pharmaceuticals

Biotechnology

SIC Code:

2834NAICS listing »

2836NAICS listing »

Top Competitors or Alternatives

Missing a competitor? Contribute!

Weigh-in!

Help the Owler community know more

Competitor - 1/1

Is Voyager Therapeutics a competitor of Ionis?

I don't know

Trending News for Ionis and Ionis's Competitors

January 28, 2020

MarketScreener

Akcea and Ionis report positive topline phase 2 study results of AKCEA-ANGPTL3-LRx

(marketscreener.com) Favorable safety and tolerability were observed Primary and multiple secondary e... See more »

January 27, 2020

BioPortfolio

Alnylam to Webcast Conference Call Discussing Fourth Quarter and Full Year 2019 Financial Results

Alnylam Pharmaceuticals Inc. Nasdaq ALNY the leading RNAi therapeutics company announced today that i... See more »

January 26, 2020

BioPortfolio

The FDA released documents that reveal a schism within the agency regarding its approval of Vyondys 53 a medicine to treat boys with Duchenne muscular dystrophy made by Sarepta Therapeutics. httpsbuff.ly2tPr51TÂ

The FDA released documents that reveal a schism within the agency regarding its approval of Vyondys 5... See more »

Competitive Analysis

TOP COMPETITORS OR ALTERNATIVES

Alnylam is one of Ionis's top competitors. Alnylam was founded in 2002, and its headquarters is in Cambridge, Massachusetts. Like Ionis, Alnylam also works within the Pharmaceuticals sector. Alnylam has 328 more employees than Ionis.

Arrowhead is Ionis's #2 rival. Arrowhead was founded in 1989 in Pasadena, California. Arrowhead operates in the Biotechnology industry. Arrowhead generates $652.2M less revenue than Ionis.

Sarepta Therapeutics is a top competitor of Ionis. Sarepta Therapeutics is a Public company that was founded in Cambridge, Massachusetts in 1980. Sarepta Therapeutics is in the Pharmaceuticals field. Sarepta Therapeutics has 238 fewer employees vs. Ionis.

RANK

COMPANY

LEADERSHIP

CEO SCORE

EMPLOYEES

TOTAL FUNDING

REVENUE

Brett P. Monia

CEO

- -
737
$267.3M
$821M
1

John Maraganore

CEO

94/100
1,065
$417.5M
$169.1M
2

Christopher Anzalone

President & CEO

80/100
113
$170.6M
$168.8M
3

Douglas S. Ingram

President & CEO

92/100
499
$292.3M
$365.1M
4

Scott Cormack

President & CEO

70/100
13
$21.5M
$14.3M
5

Joseph P Hagan

President & CEO

85/100
97
$191.5M
$6.8M
6

Andre Turenne

President & CEO

87/100
77
$205M
$73.7M
7

Neil Kumar

CEO

86/100
24
$170.3M
$26.7M
8

Angie You

CEO

81/100
50
- -
$1.2M
9

Douglas Treco

President & CEO

85/100
46
$48.2M
$5.5M
10

Jacqualyn Fouse

CEO

90/100
287
$193M
$112.5M
The top 10 competitors in Ionis' competitive set are Alnylam, Arrowhead, Sarepta Therapeutics, OncoGenex, Regulus, Voyager Therapeutics, Eidos Therapeutics, Amunix, Ra Pharma and Agios. Together they have raised over 1.7B between their estimated 2.5K employees. Ionis has 737 employees and is ranked 2nd among it's top 10 competitors. The top 10 competitors average 273.

Quarterly and Annual Revenue

Trailing 12-Months Trend (TTM)

Annual Revenue

$821M

Ionis's revenue is the ranked 1st among it's top 10 competitors. The top 10 competitors average 160.4M. Over the last three quarters, Ionis's revenue has decreased by 43.5%. Specifically, in Q3 2019's revenue was $167.9M; in Q2 2019, it was $163.8M; in Q1 2019, it was $297.2M.

Acquisitions

No recent acquisitions found related to Ionis

Ionis Funding History

Since Ionis was founded in 1989, it has participated in 4 rounds of funding. In total Ionis has raised $267.2M. Ionis' last funding round was on Jul 2017 for a total of $10.0M

ROUND

FUNDING DATE

AMOUNT

INVESTORS

Equity
Jul 2017
$10M
Series A
Dec 2015
$5M
-
Debt
Aug 2012
$201.3M
-
Equity
Aug 2005
$51M
-

Total Funding: $267.3M

Since Ionis was founded in 1989, it has participated in 4 rounds of funding. In total Ionis has raised $267.2M. Ionis' last funding round was on Jul 2017 for a total of $10.0M

Investments

COMPANY

DESCRIPTION

AMOUNT

INVESTMENT DATE

ROUND

EXIT DATE

Empirico develops a biotechnology platform that examines genomics data to develop drugs.
$17M
Jan 09, 2020
Series A
-

Ionis News

January 12, 2020San Diego Business Journal

Foundation Readies To Take On Ultra-Rare Diseases

Former Ionis CEO To Take Helm At Nonprofit.... See more »
January 10, 2020Seeking Alpha

Akcea and Ionis launch late-stage study ATTR cardiomyopathy study

See more »
January 10, 2020Pharamceutical Technology

Aro Biotherapeutics signs licensing agreement worth up to $1.4bn

Aro Biotherapeutics, a biotech firm engaged in the development of protein biologics called Centyrins,... See more »
January 10, 2020Pharmaceutical Business Review

Empirico, Ionis collaborate to develop antisense oligonucleotide therapeutics

Under the three-year collaboration, Empirico will use its Precision Insights Platform to determine th... See more »
January 9, 2020BioPortfolio

Ionis Adds Former Grail Chief Commercial Officer to Executive Team

Ionis Pharmaceuticals NASDAQ IONS appointed Onaiza CadoretManier as its chief corporate development a... See more »
January 7, 2020MarketScreener

' neurological franchise marks year of achievement

(marketscreener.com) CARLSBAD, Calif., Jan. 7, 2020 /PRNewswire/ -- The neurological franchise of Ion... See more »
December 26, 2019San Diego Business Journal

Biogen pays Ionis $45M Upfront to License Experimental Alzheimer's Drug

Carlsbad-based Ionis Pharmaceuticals recently licensed its experimental Alzheimer's drug to Biogen, e... See more »

Ionis Press Releases

August 7, 2019centralcharts

Akcea and Ionis Report Top-line Results from the BROADEN Study with WAYLIVRA® (volanesorsen) in Patients with Familial Partial Lipodystrophy

BOSTON, Mass. and CARLSBAD, Calif., Aug. 06, 2019 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDA... See more »
May 7, 2019StreetInsider

New Long-Term TEGSEDI Safety and Efficacy Data Featured as an Oral Presentation at 2019 American Academy of Neurology Annual Meeting (AAN)

BOSTON and CARLSBAD, Calif., May 07, 2019 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ: AKCA)... See more »
May 1, 2019PR Newswire

Positive clinical data at AAN 2019 reinforces Ionis' commitment to delivering life-changing medicines to patients with neurological diseases

CARLSBAD, Calif., May 1, 2019 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), the leader ... See more »
March 7, 2019StreetInsider

Ionis Pharmaceuticals to Present at Upcoming Investor Conferences

CARLSBAD, Calif., March 7, 2019 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), the leade... See more »
February 25, 2019GlobeNewswire

AKCEA-APO(a)-LRx Advances as Leading Pharmaceutical Company Exercises Option to License

Phase 3 planning and initiation activities underway... See more »
November 27, 2018centralcharts

First-in-class therapies using advanced antisense chemistries highlighted at 2018 American Society of Hematology Annual Meeting

CARLSBAD, Calif., Nov. 27, 2018 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), the leade... See more »
October 24, 2018centralcharts

Ionis Pharmaceuticals to Hold Third Quarter 2018 Financial Results Webcast

Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced today that it will host a live webcast on Tuesda... See more »

Headquarters

2855 Gazelle Court

Carlsbad, California92010

760-931-9200

Driving Directions »

Trending Companies

Summary

ABOUT

Overview

Ionis is a drug discovery company that develops and commercializes ribonucleic acid-targeted therapeutics for cardiovascular and neurological diseases Ionis was founded in 1989. Ionis' headquarters is located in Carlsbad, California, USA 92010. It has...

CEO

Ionis's CEO, Brett P. Monia, currently has an approval rating of 84%. Ionis's primary competitors are Alnylam, Arrowhead & Sarepta Therapeutics.

Website

ionispharma.com

Frequently Asked Questions about Ionis

  1. When was Ionis founded?

    Ionis was founded in 1989

  2. Who is Ionis's CEO?

    Ionis's CEO is Brett P. Monia

  3. How much revenue does Ionis generate?

    Ionis generates $821M in revenue

  4. How much funding does Ionis have?

    Ionis has historically raised $267.3M in funding

  5. Where is Ionis's headquarters?

    Ionis's headquarters is in Carlsbad California, USA

  1. How many employees does Ionis have?

    Ionis has 737 employees

  2. What sector does Ionis operate in?

    Ionis is in Pharmaceuticals, Biotechnology

  3. Who are Ionis's competitors?

    Ionis's top competitors are Alnylam, Arrowhead, Sarepta Therapeutics

  4. Who has Ionis invested in?

    Ionis's has invested in companies such as Empirico
Stay up-to-date with the latest news on Ionis